Business Description
Scancell Holdings PLC
ISIN : GB00B63D3314
Total Employee Number:
61Description
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.53 | |||||
Equity-to-Asset | -0.54 | |||||
Debt-to-Equity | -1.93 | |||||
Debt-to-EBITDA | -2.89 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -3.65 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -37.5 | |||||
3-Year FCF Growth Rate | 17 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 21.91 | |||||
9-Day RSI | 31.23 | |||||
14-Day RSI | 38.79 | |||||
3-1 Month Momentum % | 125.45 | |||||
6-1 Month Momentum % | 161.05 | |||||
12-1 Month Momentum % | 181.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.56 | |||||
Quick Ratio | 0.56 | |||||
Cash Ratio | 0.36 | |||||
Days Sales Outstanding | 44.2 | |||||
Days Payable | 4240.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.3 | |||||
Shareholder Yield % | -5.16 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 94.95 | |||||
Operating Margin % | -283.34 | |||||
Net Margin % | -116.98 | |||||
EBITDA Margin % | -118.79 | |||||
FCF Margin % | -211.02 | |||||
OCF Margin % | -180.6 | |||||
ROA % | -30.02 | |||||
ROIC % | -32.91 | |||||
3-Year ROIIC % | -11.13 | |||||
ROC (Joel Greenblatt) % | -738.76 | |||||
ROCE % | -201.65 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 33.08 | |||||
EV-to-EBIT | -29.66 | |||||
EV-to-EBITDA | -33.77 | |||||
EV-to-Forward-EBITDA | -22.7 | |||||
EV-to-Revenue | 40.12 | |||||
EV-to-Forward-Revenue | 75.6 | |||||
EV-to-FCF | -19.69 | |||||
Earnings Yield (Greenblatt) % | -3.38 | |||||
FCF Yield % | -5.56 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Scancell Holdings PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 5.51 | ||
| EPS (TTM) (€) | -0.006 | ||
| Beta | 0.7206 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 1.25 | ||
| Volatility % | 79.75 | ||
| 14-Day RSI | 38.79 | ||
| 14-Day ATR (€) | 0.015915 | ||
| 20-Day SMA (€) | 0.2066 | ||
| 12-1 Month Momentum % | 181.82 | ||
| 52-Week Range (€) | 0.064 - 0.29 | ||
| Shares Outstanding (Mil) | 1,037.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Scancell Holdings PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Scancell Holdings PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-10-30 15:00 | In 122 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-09-11 12:00 | In 73 days | ||
| Annual report for 2026 | 2026-09-11 | In 72 days | ||
| Fourth quarter earnings results for 2026 | 2026-09-11 | In 72 days | ||
| Second quarter earnings conference call for 2026 | 2026-01-29 14:00 | 0.11 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-01-29 | 0.11 (+0.00%) | ||
| General meeting for 2025 | 2025-10-30 15:00 | 0.08 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2025-09-11 12:00 | 0.08 (+23.48%) | ||
| Annual report for 2025 | 2025-09-11 | 0.08 (+23.48%) | ||
| Fourth quarter earnings results for 2025 | 2025-09-11 | 0.08 (+23.48%) |
Show
Entries
Scancell Holdings PLC Frequently Asked Questions
What is Scancell Holdings PLC(FRA:SCP)'s stock price today?
The current price of FRA:SCP is €0.16. The 52 week high of FRA:SCP is €0.29 and 52 week low is €0.06.
When is next earnings date of Scancell Holdings PLC(FRA:SCP)?
The next earnings date of Scancell Holdings PLC(FRA:SCP) is 2026-09-11 Est..
Does Scancell Holdings PLC(FRA:SCP) pay dividends? If so, how much?
Scancell Holdings PLC(FRA:SCP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Scancell Holdings PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers